Outlook Therapeutics (OTLK) Asset Writedowns and Impairment (2018 - 2020)

Outlook Therapeutics (OTLK) has reported Asset Writedowns and Impairment for 3 consecutive years, with -$27624.0 the latest figure, recorded in Q3 2020.

• In Q3 2020, Asset Writedowns and Impairment fell 100.33% year-over-year to -$27624.0; the TTM figure through Sep 2020 stood at $8.8 million (down 21.85% YoY), while the FY2020 annual figure was $500000.0, down 95.56% from the prior year.
• Asset Writedowns and Impairment eased to -$27624.0 in Q3 2020 per OTLK's latest filing, from $104296.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $8.3 million in Q3 2019 and bottomed at -$27624.0 in Q3 2020.
• Historically, Asset Writedowns and Impairment has averaged $1.7 million across 3 years, with a median of $423328.0 in 2020.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 104.8% in 2020 and fell as far as 100.33% in 2020.
• Outlook Therapeutics' Asset Writedowns and Impairment stood at $2.3 million in 2018, then surged by 253.62% to $8.3 million in 2019, then plunged by 100.33% to -$27624.0 in 2020.
• Business Quant data shows OTLK's Asset Writedowns and Impairment at -$27624.0 in Q3 2020, $104296.0 in Q2 2020, and $423328.0 in Q1 2020.